Vivek Subbiah: Incredible Panel Discussion at the Target Cancer Foundation Think Tank
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Incredible Panel Discussion with thought leaders from FDA & academia at the Target Cancer Foundation Think Tank in Boston!
Had the privilege of engaging in a thought-provoking panel discussion with the US FDA Chief, Oncology Branch, CBER, Dr. Peter Bross
His insights and years of wisdom from the FDA perspective were invaluable.
As always, our amazing Dr. Razelle Kurzrock captivated the audience with her discussion on the WINTHER and I-PREDICT studies, showcasing the power of precision medicine in oncology.
Grateful for the opportunity to be part of such an inspiring event and to collaborate with these brilliant minds. Together, we are pushing the boundaries of cancer research and improving patient outcomes.”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023